A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile

Linping Cao, MD\textsuperscript{a}, Jiawei Hong, MD\textsuperscript{b}, Yacong Wang, MD\textsuperscript{c}, Jun Yu, PhD\textsuperscript{a}, Ruobing Ma, MM\textsuperscript{d}, Jia Li, MM\textsuperscript{d}, Jian Wu, PhD\textsuperscript{a},\textsuperscript{*} Shusen Zheng, PhD\textsuperscript{a},\textsuperscript{*}

Abstract

\textbf{Rationale:} Primary splenic angiosarcoma (PSA) is a rare mesenchymal malignancy of the splenic vascular origin often with a dismal prognosis. Genomic profile may provide evidence for the solution of therapy.

\textbf{Patient concerns:} We reported a case of a 51-year-old woman with splenectomy 4 years ago and the postoperative histopathology diagnosis revealed “splenic hemangioma” with spontaneous rupture. Two years after the operation, the patient’s rechecked abdominal computed tomography (CT) showed multiple hepatic occupations.

\textbf{Diagnoses:} Pathological test suggested PSA hepatic metastasis.

\textbf{Interventions:} The patient was treated with trans-catheter arterial chemoembolization (TACE) and a pathological diagnosis of PSA was highly suspected in the hepatic biopsy. Four somatic alterations, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), Fos proto-oncogene, AP-1 transcription factor subunit (FOS), MCL1 apoptosis regulator (MCL1), and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) were detected in the tumor tissue using a Next generation sequencing (NGS) technology. The results prompted that the patient may get clinical benefit from using some agents for targeted therapy, Everolimus, Temsirolimus, or Copanlisib.

\textbf{Outcomes:} The patient refused targeted therapy. As a result, the patient passed away within 51 months after splenectomy.

\textbf{Lessons:} PSA is an aggressive disease that often presented with a high propensity for metastasis and rupture hemorrhage. Some of these mutations were first discovered in PSA and these findings added new contents to the genomic mutation profile of PSA.

\textbf{Abbreviations:} NGS = next generation sequencing, PSA = primary splenic angiosarcoma, TACE = trans-catheter arterial chemoembolization.

\textbf{Keywords:} angiosarcoma, genetic profile, hepatic metastasis, next generation sequencing, targeted therapy

1. Introduction

Primary splenic angiosarcoma (PSA) is an extremely rare mesenchymal malignancy of the splenic vascular origin with high metastatic potential. It is often life-threatening if combined with spontaneous rupture or distant metastasis.\textsuperscript{11} The incidence of this disease is of 0.14 to 0.23 cases per million, with a rate of tumor metastasis between 69\% and 100\% which mainly appear lymph node, liver, lung, bone, and thyroid metastasis. In all reported cases, about 93\% of patients died of tumor metastasis. However, the PSA liver metastasis after splenectomy is quite rare.
Here, we reported a case of a 51-year-old woman with PSA liver metastasis after splenectomy because of splenic hemangioma and rupture 3 years later. In addition, genomic profile was tested to offer more evidences for further possible targeted therapy.

2. Case presentation

The patient was 51 years old, female, with no history of smoking or family history of cancer. Four years ago, the patient underwent splenectomy for “splenic hemangioma” with spontaneous rupture (Fig. 1). Now, in a routine reviewed test, abdominal enhancement computed tomography (CT) revealed multiple hepatic occupations with annular enhancement; the enhancement gradually extended to the center of occupations at the portal vein stage and the balance stage, and hepatic metastatic malignant tumor consideration (Fig. 2). Positron emission tomography-CT examination hinted intrahepatic multiple low metabolic malignancy with extensive bone metastases (Fig. 3). The patient was treated with trans-catheter arterial chemoembolization (TACE) and a pathological diagnosis of PSA was highly suspected in the hepatic biopsy (Fig. 4). Subsequently, another TACE was performed. The re-examination of abdominal enhancement CT showed intrahepatic nodules significantly enhanced and active focus still existed around the treatment area (Fig. 5) and revealed the effect of TACE was not satisfactory. So we decided to take the hepatic specimen for further genomic profile to adjust the treatment strategy to achieve good curative effect.

Fresh tumor tissue sections and matched blood from the patient were collected and DNA was extracted from the sample. All coding exons of 450 cancer-related genes and selected introns of 39 common genes rearranged in solid tumors were captured and sequenced with a mean coverage of 1000 times for tumor tissue and 350 times for blood on Illumina NextSeq platform. Genomic alterations including base substitution,
short and long insertions/deletions, copy number variations, and gene rearrangement were assessed. Somatic alterations were obtained by comparison with matched blood control samples.

The genomic profile results indicated phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) N1044K and H1047R mutation, Fos proto-oncogene, AP-1 transcription factor subunit (FOS) amplification, MCL1 apopto-

Figure 3. PET-CT demonstrating hepatic and skeletal metastases. (A): CT scan for intrahepatic multiple FDG hypermetabolism metastases; (B): CT scan for FDG hypermetabolism metastases of the left ilium; (C): abdominal orthostatic plain film for hypermetabolism metastases. CT = computed tomography, FDG = fluorodeoxyglucose, PET = positron emission tomography.

Figure 4. Histological examination results. (A): Vascular channels lined by endothelial cells (×200). (B): Tumor cells showing positive immunohistochemistry staining for CD31 (×400).
sis regulator (MCL1) amplification, and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) c.1746–8_1770del (Figs. 6 and 7). PIK3CA mutation revealed that the patient may get clinical benefit by using Everolimus, Temsirolimus, or Copanlisib. Thus, we recommend the patient to accept targeted therapy according to the genomic profile results, but patient refused to cooperate. As a result, the patient passed away within 51 months after splenectomy.

3. Discussion

The spleen tumors are rare and the primary spleen malignancy are more rare. PSA is a very rare but aggressive malignancy with high metastatic potential. Since Langhans reports the first case of PSA in 1879, there are only approximately 200 cases reported worldwide. [1] The common age of onset was between 50 and 79 years, [2] and about 86% of the patients appeared hepatic metastases. [2] The average survival time was between 4.4 and 14 months, and only about 20% of patients can survive longer than 6 months. PSA needed systemic therapy including splenectomy and chemotherapy. [3] Hsu et al. [4] reported that patient with PSA required the metastases. [2] The average survival time was between 4.4 and 14 months, and only about 20% of patients can survive longer than 6 months. PSA needed systemic therapy including splenectomy and chemotherapy. [3] Hsu et al. [4] reported that patient with PSA had a maximum survival of 14.8 years after splenectomy.

PSA originated from the vessel endothelial cells of the spleen, while the pathogenesis is not clear yet. It may be caused by exposure to carcinogens and chemo-radio therapy for malignant tumors. [2] It has been reported that the angiosarcoma requires the existence of a benign pathology such as hemangioma or hemangioendothelioma; however, the patients did not have a history of those diseases in many cases. [5] For the present case, the patient had a splenic hemangioendothelioma and spontaneous rupture before and it might act as a precursor to angiosarcoma.

The clinical manifestations of PSA vary greatly. Left upper abdominal pain is the most common presentation (about 80%), and other complaints include upper abdominal mass, fatigue, anorexia, weight loss, and dyspnea. Spontaneous rupture hemorrhage is the most serious symptom. There are also reports of unexplained fever and anemia in patient with PSA. [7] Mild to moderate anemia is the major finding of blood routine examination in PSA (about 70%–80%, hemoglobin <100 g/L), [8] and other major abnormalities include thrombocytopenia (more than half, thrombocyte count <100×10^9/L), [9] leukopenia (about 20%, leukocyte count <4×10^9/L), erythrocyte sedimentation rate enhancement (15%). [10]

PSA needed to be differential diagnosis with lymphoma, splenic metastatic tumor, splenic vascular benign tumor, splenic abscess, and other splenic diseases. [11] Imaging examination (ultrasound, CT, and magnetic resonance imaging [MRI]) is the main diagnostic and differential diagnostic method for PSA. However, due to lack of typical performance, imaging examination is inaccurate sometimes. [11] CT is the most commonly used method for PSA, which is of high value in the evaluation of general characteristics and complications of PSA. On CT scan imaging, splenic heterogeneous mass can be observed in 60% of cases. [12,13] The abdomen enhanced CT scan shows significant differences between the enhanced region and non-enhanced region of the spleen immediately after the injection of contrast medium. The non-enhanced region is mostly poor blood supply or avascular necrosis focus, which begins to intensify after 10 to 50 minutes, and that is referred as PSA delayed enhancement sign. This can be identified with lymphoma and splenic metastasis which don’t have such sign. [11,14] Active bleeding signs can be seen in PSA patients. On MRI scan, both T1-weighted and T2-weighted images reveal nodular lesions with decreased or increased signal intensity which is related to necrosis, hemorrhage or fibrosis within the tumor, [16] and most patients can have a T2 high density image. [13]

Pathological examination and immunohistochemistry are generally considered to be the golden standard for PSA diagnosis. [2] PSA has the typical characteristics of angiogenic malignancy, including vascular structures, highly atypical cell morphology, hyperchromatic and prominent nucleoli, and typical mitotic sign can be seen in some specimens. Highly, spleen puncture biopsy is considered as a relative contraindication because it may cause splenic rupture. Therefore, histological examination is performed only after splenectomy in such cases. Recently, fine-needle aspiration cytology which used a 22-gauge or smaller needle is identified as safe as postoperative biopsy, [15,16] but hemorrhage occurs after biopsy in few cases. PSA presents 2-way feature of positive vascular endothelial markers and histiocytic markers in immunohistochemistry. Previous studies reveal that at least 2 endothelial markers (CD34, CD31, FVIIIRAg, or VEGFR3, etc.) and 1 histiocytic...
Figure 6. The mutation of PIK3CA and PIK3R1. (A): the 1047th histidine codon mutating into arginine codon; (B): the 1044th asparagine codon mutating into lysine codon; (C): the deficiency of bp in 3’ terminal 8th to 1770th of PIK3R1 13th intron. PIK3CA = phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, PIK3R1 = phosphoinositide-3-kinase regulatory subunit 1.

Figure 7. The amplification of FOS and MCL1. FOS = Fos proto-oncogene, AP-1 transcription factor subunit, MCL1 = MCL1 apoptosis regulator.
marker (CD68 or lysozyme, etc.) will be positive. Most patients are positive for both CD31 and CD34. CD31 is a marker of vascular endothelial differentiation, and the sensitivity and specificity of CD31 in PSA diagnosis are >90%. CD34 also suggests vascular endothelial origin. In this case, immunohistochemistry examination was not very helpful for the diagnosis, all the cell markers above were negative except CD31 (Fig. 4).

Genomic profile is a technique for detecting cellular DNA by collecting fresh tissue sections from the patient. The PSA can appear multiple cytogenetic changes represented by the mutations of chromosomal copies, as well as the mutant gene including K-ras, p53, PIK3CA, TP53, PTEN, PLCG1, Hras, etc. In our case, the patient’s genomic profile showed PIK3CA, FOS, MCL1, and PIK3R1 mutation and were not the same as the previous reports. The mutation of PIK3CA gene, where the 1044 asparagine codon mutating into lysine codon and the 1047 histidine codon mutating into arginine codon (Fig. 6), increase the catalytic activity of PIK3CA, thereby enhancing the downstream signal conduction, tumor malignant transformation, and tumor cell migration. Everolimus, Temsirolimus (mTOR inhibitor of the PI3K/Akt/mTOR signaling path), and Copanlisib (PI3K inhibitor) can be used as a targeted treatment. The gene amplification of FOS and MCL1 (Fig. 7) might affect their mRNA and protein expression levels, however, there is a lack of anti-tumor drugs targeting FOS and MCL1 clinically now.

Radical surgical treatment is the major treatment for patients with PSA. Splenectomy before splenic spontaneous rupture can significantly prolong the survival of patients better than after. But for the majority of patients with PSA, distant metastasis had already occurred at the time of diagnosis, so splenectomy was seen as an approach more for diagnostic purpose rather than curative purpose. In addition, PSA had the high risk of distant metastasis and local recurrence after splenectomy. Postoperative metastasis was the most significant factor affecting the prognosis of patients. The postoperative radiotherapy or chemotherapy is still a controversial treatment option because there is no evidence statistical data to this disease. Neuhausser et al. reported some patients received adjuvant chemotherapy after splenectomy and 1 patient survived with the disease for 8 years, another was disease-free for 10 years. Paclitaxel was considered as an adjuvant and neoadjuvant therapy by Vakkalanka and Milhem, suggesting that chemotherapy may decrease local recurrence and improve overall survival. De Azevedo et al. also reported a patient remained disease free for 1 year and 2 months after paclitaxel adjuvant chemotherapy. Hara et al. presented a patient who received autologous peripheral blood stem cell transplantation combined with high-dose chemotherapy after splenectomy. The treatment brought 6-year-long complete remission. Recently, Kohutek et al. presented a patient who underwent radical splenectomy for primary angiosarcoma of the spleen. Palliative radiotherapy, bisphosphonates, doxorubicin, and paclitaxel chemotherapy can significantly prolonged periods of disease stabilization. They think durable benefit can be achieved in some patients with multimodality management. As for the targeting therapy, there were few experiences. Our patient received twice transcatheter arterial chemoembolization (TACE, using palonosetron + ptimegodine + iodipin the first time and palonosetron + pharmorubicin + iodipin the second time) 3 years after splenectomy, but the results were unsatisfactory.

4. Conclusion

PSA is an aggressive disease that often presented with a high propensity for metastasis and rupture hemorrhage. The diagnosis mainly depends on histological examination and immunohistochemistry. The diagnosis of primary splenic angiosarcoma hepatic metastasis was confirmed by pathological examinations twice. Although the case has made some reports, it occurred after splenectomy is quite rare. For patients with poor response for conventional treatment, relative targeted therapy after genetic profile detection might achieve certain efficacy. Unfortunately, due to the patient refusing the target therapy, we cannot understand the therapeutic effect of targeted therapy in PSA. This is the main limitation and regret of this study.

Author contributions

Conceptualization: Jian Wu, Shusen Zheng.
Data curation: Jiawei Hong, Jun Yu.
Formal analysis: Yacong Wang, Jia Li.
Investigation: Linping Cao, Jun Yu.
Project administration: Linping Cao.
Software: Ruobing Ma, Jia Li.
Validation: Ruobing Ma.
Writing – original draft: Jiawei Hong.
Writing – review & editing: Jian Wu, Shusen Zheng.

References

[1] Duan YF, Jiang Y, Wu CX, et al. Spontaneous rupture of primary splenic angiosarcoma: a case report and literature review. World J Surg Oncol 2013;11:53.
[2] Chen F, Jin HF, Fan YH, et al. Case report of primary splenic angiosarcoma with hepatic metastases. World J Gastroenterol 2015;21:11199–204.
[3] Ferreira BP, Rodler ET, Loggers ET, et al. Systemic therapy in primary angiosarcoma of the spleen. Rare tumors 2012;4:455.
[4] Hou JT, Ueng SH, Hwang TL, et al. Primary angiosarcoma of the spleen in a child with long-term survival. Pediatr Surg Int 2007;23:807–10.
[5] Chen X, Li H, Wang F, et al. Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: a case-compliant case report and literature review. Medicine (Baltimore) 2018;97:e9718.
[6] Liu Z, Du X, Li H, et al. Primary splenic angiosarcoma. Vasa 2012;41:57–62.
[7] Deng R, Chang W, Wu X, et al. Primary splenic angiosarcoma with fever and anemia: a case report and literature review. Int J Clin Exp Pathol 2013;6:41040-4.
[8] Yoshida K, Endo T, Kamata K, et al. [A case of angiosarcoma of the spleen with intraperitoneal bleeding]. Nihon Shokakibyo Gakkai Zasshi 2014;111:549–56.
[9] Naseem S, Varma N, Das R, et al. Pediatric patients with bictyopenia/pancytopenia: review of etiologies and clinico-hematological profile at a tertiary center. Indian J Pathol Microbiol 2013;54:75–80.
[10] Plotnik AN, Schneider P, Tsai A, et al. Splenic angiosarcoma metastasis to the brain. J Clin Neurosci 2008;15:927–9.

Cao et al. Medicine (2019) 98:28
[11] Batouli A, Fairbrother SW, Silverman JF, et al. Primary splenic angiosarcoma: clinical and imaging manifestations of this rare aggressive neoplasm. Curr Probl Diagn Radiol 2016;45:284–7.
[12] Thompson WM, Levy AD, Aguilara NS, et al. Angiosarcoma of the spleen: imaging characteristics in 12 patients. Radiology 2005;235:106–15.
[13] Vrachliotis TG, Bennett WF, Vaswani KK, et al. Primary angiosarcoma of the spleen–CT, MR, and sonographic characteristics: report of two cases. Abdom Imaging 2000;25:283–5.
[14] Reddy SC, Reddy SC. Hemangiosarcoma of the spleen: helical computed tomography features. South Med J 2000;93:825–7.
[15] Delacruz V, Jorda M, Gomez-Fernandez C, et al. Fine-needle aspiration diagnosis of angiosarcoma of the spleen: a case report and review of the literature. Arch Pathol Lab Med 2005;129:1054–6.
[16] Lal A, Ariga R, Gattuso P, et al. Splenic fine needle aspiration and core biopsy. A review of 49 cases. Acta Cytol 2003;47:951–9.
[17] Abdallah RA, Abdou AG, Asaad NY, et al. Primary epithelioid angiosarcoma of spleen: a case report and review of literature. J Clin Diagn Res 2016;10:ED05–7.
[18] Xu L, Zhang Y, Zhao H, et al. Well-differentiated angiosarcoma of spleen: a teaching case mimicking hemangioendothelioma and cytogenetic analysis with array comparative genomic hybridization. World J Surg Oncol 2015;13:300.
[19] Wang G, Wu M, Maloneyhuss MA, et al. Actionable mutations in canine hemangiosarcoma. PLoS One 2017;12:e0188667.
[20] Dogrueluk T, Tsang YH, Espitia M, et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res 2015;75:5341–54.
[21] Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802–7.
[22] Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006;44:151–7.
[23] Song L, Coppola D, Livingston S, et al. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005;4:267–76.
[24] Cizkova M, Vacher S, Meseure D, et al. PI3KR1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 2013; 13:345.
[25] Wheler JJ, Atkins JT, Janku F, et al. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer 2015;15:442.
[26] Shukla M, Basu S, Shukla V, et al. Fever, anemia, and splenomegaly: a rare presentation of splenic angiosarcoma. Indian J Med Paediatr Oncol 2011;32:230–2.
[27] Neuhauser TS, Derringer GA, Thompson LD, et al. Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases. Mod Pathol 2000;13:978–87.
[28] Vakkalanka B, Milhem M. Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. Clin Med Insights Oncol 2010;4:107–10.
[29] de Azevedo O, do Nascimento Santos B, de Souza Liboni N, et al. Splenic angiosarcoma: a diagnostic splenectomy finding. Case Rep Oncol 2016; 9:733–7.
[30] Hara T, Tsurumi H, Kasahara S, et al. Long-term survival of a patient with splenic angiosarcoma after resection, high-dose chemotherapy, and autologous peripheral blood stem cell transplantation. Intern Med 2010;49:2253–7.
[31] Kohutek F, Badik L, Bystricky B. Primary angiosarcoma of the spleen: rare diagnosis with atypical clinical course. Case Rep Oncol Med 2016;2016:4901726.